A citation-based method for searching scientific literature

Patrick Grossmann, Simona Cristea, Niko Beerenwinkel. BMC Evol Biol 2020
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer.
Michael J Pishvaian, Ignacio Garrido-Laguna, Stephen V Liu, Pratik S Multani, Edna Chow-Maneval, Christian Rolfo. JCO Precis Oncol 2018
5
100

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
100

Recent advances in precision oncology research.
Ann M Bode, Zigang Dong. NPJ Precis Oncol 2018
29
100

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
Andrew J Aguirre, Nabeel Bardeesy, Manisha Sinha, Lyle Lopez, David A Tuveson, James Horner, Mark S Redston, Ronald A DePinho. Genes Dev 2003
738
100

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
43
100

Cancer evolution: mathematical models and computational inference.
Niko Beerenwinkel, Roland F Schwarz, Moritz Gerstung, Florian Markowetz. Syst Biol 2015
154
100

Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival.
Vincent P Groot, Alex B Blair, Georgios Gemenetzis, Ding Ding, Richard A Burkhart, A Floortje van Oosten, I Quintus Molenaar, John L Cameron, Matthew J Weiss, Stephen C Yang,[...]. HPB (Oxford) 2019
12
100




Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
100

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.
Justin F Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo-Jack, Luc Friboulet, Jessica J Lin, Harper G Hubbeling, Leila Dardaei, Anna F Farago, Katherine R Schultz,[...]. JCO Precis Oncol 2017
141
100

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
Agrin Moeini, Daniela Sia, Nabeel Bardeesy, Vincenzo Mazzaferro, Josep M Llovet. Clin Cancer Res 2016
135
100

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Paola Ulivi, Elisa Chiadini, Claudio Dazzi, Alessandra Dubini, Matteo Costantini, Laura Medri, Maurizio Puccetti, Laura Capelli, Daniele Calistri, Alberto Verlicchi,[...]. Clin Lung Cancer 2016
61
100

Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer.
Stephan Kruger, Michael Haas, Philipp Johannes Burger, Steffen Ormanns, Dominik Paul Modest, Christoph Benedikt Westphalen, Marlies Michl, Axel Kleespies, Martin Kurt Angele, Werner Hartwig,[...]. Pancreatology 2016
37
100

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon,[...]. Clin Cancer Res 2016
88
100

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Monika A Davare, Nadeem A Vellore, Jacob P Wagner, Christopher A Eide, James R Goodman, Alexander Drilon, Michael W Deininger, Thomas O'Hare, Brian J Druker. Proc Natl Acad Sci U S A 2015
67
100

Precision medicine in pancreatic cancer: treating every patient as an exception.
Brian Herbst, Lei Zheng. Lancet Gastroenterol Hepatol 2019
20
100

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
Bo Mi Ku, Yeon Hee Bae, Kyoung Young Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Invest New Drugs 2020
17
100

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
100

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari,[...]. Ann Oncol 2019
144
100

Novel Indications for Surgical Resection of Metachronous Lung Metastases From Pancreatic Cancer After Curative Resection.
Masao Nakajima, Tomio Ueno, Nobuaki Suzuki, Hiroto Matsui, Yoshitaro Shindo, Kazuhiko Sakamoto, Yoshihiro Tokuhisa, Yukio Tokumitsu, Shigeru Takeda, Shigefumi Yoshino,[...]. J Clin Gastroenterol 2017
12
100

Accumulation of driver and passenger mutations during tumor progression.
Ivana Bozic, Tibor Antal, Hisashi Ohtsuki, Hannah Carter, Dewey Kim, Sining Chen, Rachel Karchin, Kenneth W Kinzler, Bert Vogelstein, Martin A Nowak. Proc Natl Acad Sci U S A 2010
469
100

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Caroline E McCoach, Anh T Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D Davies, Daniel T Merrick, Paul A Bunn,[...]. Clin Cancer Res 2018
121
100

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.
Derrick S Haslem, Ingo Chakravarty, Gail Fulde, Heather Gilbert, Brian P Tudor, Karen Lin, James M Ford, Lincoln D Nadauld. Oncotarget 2018
25
100

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Aatur D Singhi, Ben George, Joel R Greenbowe, Jon Chung, James Suh, Anirban Maitra, Samuel J Klempner, Andrew Hendifar, Javle M Milind, Talia Golan,[...]. Gastroenterology 2019
124
100

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
Christine M Lovly, Abha Gupta, Doron Lipson, Geoff Otto, Tina Brennan, Catherine T Chung, Scott C Borinstein, Jeffrey S Ross, Philip J Stephens, Vincent A Miller,[...]. Cancer Discov 2014
234
100

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
842
100

Clonal evolution in cancer.
Mel Greaves, Carlo C Maley. Nature 2012
100

Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
Saul Campos-Gomez, Humberto Lara-Guerra, Mark J Routbort, Xinyan Lu, George R Simon. Int J Biol Markers 2015
10
100

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
100

Melanoma.
Dirk Schadendorf, Alexander C J van Akkooi, Carola Berking, Klaus G Griewank, Ralf Gutzmer, Axel Hauschild, Andreas Stang, Alexander Roesch, Selma Ugurel. Lancet 2018
490
100

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Helen Y Zou, Luc Friboulet, David P Kodack, Lars D Engstrom, Qiuhua Li, Melissa West, Ruth W Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang,[...]. Cancer Cell 2015
274
100

Oligometastatic Disease in Pancreatic Cancer - How to Proceed?
Bernhard W Renz, Stefan Boeck, Falk Roeder, Christoph Trumm, Volker Heinemann, Jens Werner. Visc Med 2017
24
100

Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.
Jake June-Koo Lee, Seongyeol Park, Hansol Park, Sehui Kim, Jongkeun Lee, Junehawk Lee, Jeonghwan Youk, Kijong Yi, Yohan An, In Kyu Park,[...]. Cell 2019
83
100

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.
Sunil R Hingorani, Emanuel F Petricoin, Anirban Maitra, Vinodh Rajapakse, Catrina King, Michael A Jacobetz, Sally Ross, Thomas P Conrads, Timothy D Veenstra, Ben A Hitt,[...]. Cancer Cell 2003
100

ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
Florian Guisier, Nicolas Piton, Mathieu Salaun, Luc Thiberville. Clin Lung Cancer 2019
9
100

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.
Hiroki Sato, Adam J Schoenfeld, Evan Siau, Yue Christine Lu, Huichun Tai, Ken Suzawa, Daisuke Kubota, Allan J W Lui, Besnik Qeriqi, Marissa Mattar,[...]. Clin Cancer Res 2020
17
100

Molecular epidemiology and diagnostics of KRAS mutations in human cancer.
Jozsef Timar, Karl Kashofer. Cancer Metastasis Rev 2020
39
100

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
363
100

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
Sunil R Hingorani, Lifu Wang, Asha S Multani, Chelsea Combs, Therese B Deramaudt, Ralph H Hruban, Anil K Rustgi, Sandy Chang, David A Tuveson. Cancer Cell 2005
100

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
Nicolas Guibert, Fabrice Barlesi, Renaud Descourt, Hervé Léna, Benjamin Besse, Michèle Beau-Faller, Jean Mosser, Eric Pichon, Jean-Philippe Merlio, L'Houcine Ouafik,[...]. J Thorac Oncol 2017
39
100

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
100

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
163
100

Checkpoint inhibitors in pancreatic cancer.
Andreas Henriksen, Anne Dyhl-Polk, Inna Chen, Dorte Nielsen. Cancer Treat Rev 2019
74
100

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Monika A Davare, Jacob J Henderson, Anupriya Agarwal, Jacob P Wagner, Sudarshan R Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W Gilheeney, Ana DeCarvalo,[...]. Clin Cancer Res 2018
24
100

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Ahnah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, Dae Seog Heo. Clin Cancer Res 2015
89
100

Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal.
Basile Tessier-Cloutier, Ellen Cai, David F Schaeffer. Diagn Pathol 2019
2
100

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima,[...]. Nat Commun 2019
61
100

EML4-ALK fusion in lung.
Hiroyuki Mano, Kengo Takeuchi. Am J Pathol 2010
12
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.